Brainstorm Cell Therapeutics (BCLI) Reports Q1 Loss of $0.12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
May 14, 2018 8:00 AM EDTNEW YORK, N.Y. and PETACH TIKVAH, Israel, May 14, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2018.
"We are very pleased with the progress we are making with our ongoing Phase... More
